Eli Lilly And Co (LLY) Shares Sold by Cullinan Associates Inc.

Cullinan Associates Inc. trimmed its holdings in Eli Lilly And Co (NYSE:LLY) by 5.0% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 50,625 shares of the company’s stock after selling 2,642 shares during the quarter. Cullinan Associates Inc.’s holdings in Eli Lilly And Co were worth $5,858,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Vanguard Group Inc. boosted its holdings in shares of Eli Lilly And Co by 0.7% in the third quarter. Vanguard Group Inc. now owns 74,132,985 shares of the company’s stock valued at $7,955,211,000 after acquiring an additional 511,752 shares during the period. Vanguard Group Inc boosted its holdings in shares of Eli Lilly And Co by 0.7% in the third quarter. Vanguard Group Inc now owns 74,132,985 shares of the company’s stock valued at $7,955,211,000 after acquiring an additional 511,752 shares during the period. BlackRock Inc. boosted its holdings in shares of Eli Lilly And Co by 0.4% in the third quarter. BlackRock Inc. now owns 66,925,674 shares of the company’s stock valued at $7,181,792,000 after acquiring an additional 280,777 shares during the period. Capital International Investors boosted its holdings in shares of Eli Lilly And Co by 7.6% in the third quarter. Capital International Investors now owns 10,237,075 shares of the company’s stock valued at $1,098,541,000 after acquiring an additional 722,431 shares during the period. Finally, Bank of New York Mellon Corp boosted its holdings in shares of Eli Lilly And Co by 0.3% in the third quarter. Bank of New York Mellon Corp now owns 9,501,142 shares of the company’s stock valued at $1,019,568,000 after acquiring an additional 27,009 shares during the period. 77.02% of the stock is owned by hedge funds and other institutional investors.

Several equities research analysts have recently weighed in on LLY shares. Cantor Fitzgerald set a $110.00 price objective on Eli Lilly And Co and gave the company a “buy” rating in a report on Monday, September 17th. Barclays reissued an “overweight” rating and issued a $112.00 price objective (up from $107.00) on shares of Eli Lilly And Co in a report on Tuesday, September 18th. JPMorgan Chase & Co. set a $117.00 price target on Eli Lilly And Co and gave the stock an “overweight” rating in a research note on Wednesday, September 26th. Zacks Investment Research cut Eli Lilly And Co from a “buy” rating to a “hold” rating in a research note on Friday, September 28th. Finally, SunTrust Banks upped their price target on Eli Lilly And Co from $105.00 to $123.00 and gave the stock a “buy” rating in a research note on Monday, October 1st. Ten investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $111.50.

Shares of Eli Lilly And Co stock traded down $0.75 during trading hours on Friday, hitting $115.19. 1,130,850 shares of the company were exchanged, compared to its average volume of 5,031,224. Eli Lilly And Co has a 1 year low of $73.69 and a 1 year high of $119.84. The company has a debt-to-equity ratio of 0.83, a current ratio of 1.91 and a quick ratio of 1.53. The stock has a market capitalization of $124.16 billion, a PE ratio of 26.91, a price-to-earnings-growth ratio of 1.68 and a beta of 0.33.

Eli Lilly And Co (NYSE:LLY) last released its quarterly earnings data on Tuesday, November 6th. The company reported $1.39 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.35 by $0.04. The firm had revenue of $6.06 billion during the quarter, compared to analysts’ expectations of $6.04 billion. Eli Lilly And Co had a return on equity of 42.84% and a net margin of 1.85%. Eli Lilly And Co’s revenue was up 7.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.05 earnings per share. As a group, equities research analysts anticipate that Eli Lilly And Co will post 5.59 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 8th. Shareholders of record on Friday, February 15th will be given a $0.645 dividend. This is a boost from Eli Lilly And Co’s previous quarterly dividend of $0.56. The ex-dividend date is Thursday, February 14th. This represents a $2.58 annualized dividend and a yield of 2.24%. Eli Lilly And Co’s dividend payout ratio is presently 52.57%.

In other Eli Lilly And Co news, SVP Myles O’neill sold 25,000 shares of the stock in a transaction on Monday, December 10th. The stock was sold at an average price of $112.92, for a total value of $2,823,000.00. Following the completion of the transaction, the senior vice president now owns 26,562 shares in the company, valued at $2,999,381.04. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Lilly Endowment Inc sold 174,696 shares of the stock in a transaction on Wednesday, October 17th. The stock was sold at an average price of $113.25, for a total value of $19,784,322.00. Following the completion of the transaction, the insider now owns 119,005,804 shares of the company’s stock, valued at approximately $13,477,407,303. The disclosure for this sale can be found here. Insiders sold 1,702,736 shares of company stock valued at $124,427,811 in the last quarter. 0.11% of the stock is currently owned by company insiders.

COPYRIGHT VIOLATION WARNING: This story was reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this story on another website, it was stolen and reposted in violation of international trademark & copyright laws. The legal version of this story can be accessed at https://www.thelincolnianonline.com/2019/01/11/eli-lilly-and-co-lly-shares-sold-by-cullinan-associates-inc.html.

Eli Lilly And Co Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Read More: Consumer behavior in bull markets

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply